Chronic Hepatitis B Infection Clinical Trial
Official title:
The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Pegylated Interferon α-2a and Entecavir(ETV) Treatment in Patients With Chronic Hepatitis B.
Pegylated interferon(IFN) α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while entecavir(ETV) drugs only inhibit viral replication. In hepatitis B infection, Plasmacytoid Dendritic Cells（pDCs） are the main effector cells in early antiviral innate immune response. This study was aimed at investigating the changes of pDCs frequency and function, and the expression of costimulatory molecules CD86(Cluster of Differentiation antigen 86) during Peg-IFN-αand entecavir(ETV) therapy.Meanwhile, investigators want to verify whether Peg-IFN-α suppressed the virus and the reduction of virus led to the recovery of pDCs function, or Peg-IFN-α enhanced pDCs function which gave rise to the decline of the virus.
Pegylated interferon α-2a(Peg-IFN-α)and entecavir(ETV) drugs can inhibit viral replication , but Peg-IFN-α also play an important role in immune regulation . In hepatitis B infection, Plasmacytoid Dendritic Cells (pDCs) are the main effector cells in early antiviral innate immune response.Peg-IFN-α recommended as the first-line treatment has a higher chance to achieve HBeAg seroconversion and even HBsAg disappearance than entecavir(ETV) drugs, which may be related to the functional activation of pDCs in the case of hepatitis and the function enhancement of pDCs during Peg-IFN-α therapy. This study was aimed at investigating the changes of pDCs frequency and function, and the expression of costimulatory molecules CD86 during Peg-IFN-αandentecavir(ETV) therapy.Meanwhile,investigators want to explore whether the decline of HBsAg and HBeAg resulted in recovery of CD86+pDC function, or recovery of CD86 + pDC function led to the decrease of HBsAg and HBeAg. Several studies demonstrated that HBsAg and HBeAg could damage pDC function, and the loss of HBsAg and HBeAg led to recovery of CD86+pDC function. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03329820 -
Quality of Life and Health Utility of Patients With CHB Infections
|
N/A | |
| Recruiting |
NCT04030039 -
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
|
||
| Recruiting |
NCT03209011 -
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT03210493 -
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
|
N/A | |
| Recruiting |
NCT03210506 -
The Changes of Cytokines During Antiviral Therapy
|
N/A | |
| Recruiting |
NCT03209037 -
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT03208998 -
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT04638439 -
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
|
Phase 1 | |
| Recruiting |
NCT03587467 -
Study on Gut Microbiota in Chronic HBV Infected Patients
|
||
| Completed |
NCT05355467 -
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum
|
Phase 4 | |
| Recruiting |
NCT04135235 -
Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
|